{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:02:45Z","timestamp":1790294565493,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04411-1","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:55:25Z","timestamp":1783155325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A low-dose self-amplifying mRNA vaccine encoding HPV16 E6\/E7 induces potent T-cell immunity and antitumor protection in mice"],"prefix":"10.1007","volume":"75","author":[{"given":"Rui","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujie","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyun","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"4411_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-67452-6_1","volume":"1313","author":"FS Alhamlan","year":"2021","unstructured":"Alhamlan FS, Alfageeh MB, Mushait MA, Al-Badawi MA, Al-Ahdal IA, Al-Ahdal MN (2021) Human papillomavirus-associated cancers. Adv Exp Med Biol 1313:1\u201314","journal-title":"Adv Exp Med Biol"},{"key":"4411_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"4411_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ijgo.13865","volume":"155","author":"N Bhatla","year":"2021","unstructured":"Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R (2021) Cancer of the cervix uteri: 2021 update. Int J Gynaecol Obstet 155:28\u201344","journal-title":"Int J Gynaecol Obstet"},{"key":"4411_CR4","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"4411_CR5","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41568-021-00396-4","volume":"21","author":"K Alfaro","year":"2021","unstructured":"Alfaro K, Maza M, Cremer M, Masch R, Soler M (2021) Removing global barriers to cervical cancer prevention and moving towards elimination. Nat Rev Cancer 21:607\u2013608","journal-title":"Nat Rev Cancer"},{"key":"4411_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.805695","volume":"12","author":"Z Yousefi","year":"2021","unstructured":"Yousefi Z, Aria H, Ghaedrahmati F, Bakhtiari T, Azizi M, Bastan R et al (2021) An update on Human Papilloma Virus vaccines: history, types, protection, and efficacy. Front Immunol 12:805695","journal-title":"Front Immunol"},{"key":"4411_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.03116","volume":"10","author":"A Pal","year":"2020","unstructured":"Pal A, Kundu R (2020) Human papillomavirus E6 and E7: the cervical cancer hallmarks and targets for therapy. Front Microbiol 10:3116","journal-title":"Front Microbiol"},{"key":"4411_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ygyno.2005.09.040","volume":"100","author":"AD Santin","year":"2006","unstructured":"Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R et al (2006) HPV16\/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol 100:469\u2013478","journal-title":"Gynecol Oncol"},{"key":"4411_CR9","doi-asserted-by":"publisher","first-page":"e03224","DOI":"10.1128\/mBio.03224-20","volume":"12","author":"S Peng","year":"2021","unstructured":"Peng S, Ferrall L, Gaillard S, Wang C, Chi W, Huang C et al (2021) Development of a DNA vaccine targeting E6 and E7 proteins of human papillomavirus 16 and 18 for immunotherapy in combination with recombinant vaccinia boost and PD-1 antibody. MBio 12:e03224-e3320. https:\/\/doi.org\/10.1128\/mBio.03224-20","journal-title":"MBio"},{"key":"4411_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29685","volume":"96","author":"IL Cigno","year":"2024","unstructured":"Cigno IL, Calati F, Girone C, Catozzo M, Gariglio M (2024) High-risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: uncovering mechanisms of immune evasion and therapeutic prospects. J Med Virol 96:e29685","journal-title":"J Med Virol"},{"key":"4411_CR11","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/j.ymthe.2024.04.036","volume":"32","author":"J Wang","year":"2024","unstructured":"Wang J, Wang Q, Ma L, Lv K, Han L, Chen Y et al (2024) Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies. Mol Ther 32:2340\u20132356","journal-title":"Mol Ther"},{"key":"4411_CR12","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1080\/21645515.2020.1823778","volume":"17","author":"PK Bhuyan","year":"2021","unstructured":"Bhuyan PK, Dallas M, Kraynyak K, Herring T, Morrow M, Boyer J et al (2021) Durability of response to VGX-3100 treatment of HPV16\/18 positive cervical HSIL. Hum Vaccin Immunother 17:1288\u20131293","journal-title":"Hum Vaccin Immunother"},{"key":"4411_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/v14020239","volume":"14","author":"J Tang","year":"2022","unstructured":"Tang J, Li M, Zhao C, Shen D, Liu L, Zhang X et al (2022) Therapeutic DNA vaccines against HPV-related malignancies: promising leads from clinical trials. Viruses 14:239","journal-title":"Viruses"},{"key":"4411_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9101187","volume":"9","author":"K Lundstrom","year":"2021","unstructured":"Lundstrom K (2021) Self-replicating RNA viruses for vaccine development against infectious diseases and cancer. Vaccines (Basel) 9:1187","journal-title":"Vaccines (Basel)"},{"key":"4411_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","volume":"28","author":"K Bloom","year":"2021","unstructured":"Bloom K, van den Berg F, Arbuthnot P (2021) Self-amplifying RNA vaccines for infectious diseases. Gene Ther 28:117\u2013129","journal-title":"Gene Ther"},{"key":"4411_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.omtm.2022.03.013","volume":"25","author":"G Palladino","year":"2022","unstructured":"Palladino G, Chang C, Lee C, Music N, Souza ID, Nolasco J et al (2022) Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models. Mol Ther Methods Clin Dev 25:225\u2013235","journal-title":"Mol Ther Methods Clin Dev"},{"key":"4411_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba5068","volume":"6","author":"K Luisi","year":"2020","unstructured":"Luisi K, Morabito KM, Burgomaster KE, Sharma M, Kong WP, Foreman BM et al (2020) Development of a potent Zika virus vaccine using self-amplifying messenger RNA. Sci Adv 6:eaba5068","journal-title":"Sci Adv"},{"key":"4411_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/pathogens12010138","volume":"12","author":"C Schmidt","year":"2023","unstructured":"Schmidt C, Schnierle BS (2023) Self-amplifying RNA vaccine candidates: alternative platforms for mRNA vaccine development. Pathogens 12:138","journal-title":"Pathogens"},{"key":"4411_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.103341","volume":"27","author":"MM Pourseif","year":"2022","unstructured":"Pourseif MM, Masoudi-Sobhanzadeh Y, Azari E, Parvizpour S, Barar J, Ansari R et al (2022) Self-amplifying mRNA vaccines: mode of action, design, development and optimization. Drug Discov Today 27:103341","journal-title":"Drug Discov Today"},{"key":"4411_CR20","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1099\/jgv.0.000249","volume":"96","author":"JC Rupp","year":"2015","unstructured":"Rupp JC, Sokoloski KJ, Gebhart NN, Hardy RW (2015) Alphavirus RNA synthesis and non-structural protein functions. J Gen Virol 96:2483\u20132500","journal-title":"J Gen Virol"},{"key":"4411_CR21","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","volume":"26","author":"AB Vogel","year":"2018","unstructured":"Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC et al (2018) Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther 26:446\u2013455","journal-title":"Mol Ther"},{"key":"4411_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145130","volume":"21","author":"K Lundstrom","year":"2020","unstructured":"Lundstrom K (2020) Self-amplifying RNA viruses as RNA vaccines. Int J Mol Sci 21:5130","journal-title":"Int J Mol Sci"},{"key":"4411_CR23","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/10548","volume":"5","author":"H Ying","year":"1999","unstructured":"Ying H, Zaks TZ, Wang R-F, Irvine KR, Kammula US, Marincola FM, Leitner WW, Restifo NP (1999) Cancer therapy using a self-replicating RNA vaccine. Nat Med 5:823\u2013827","journal-title":"Nat Med"},{"key":"4411_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1487913","volume":"7","author":"S van de Wall","year":"2018","unstructured":"van de Wall S, Ljungberg K, Ip PP, Boerma A, Knudsen ML, Nijman HW, Liljestr\u00f6m P, Daemen T (2018) Potent therapeutic efficacy of an Alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens. OncoImmunology 7:e1487913","journal-title":"OncoImmunology"},{"key":"4411_CR25","unstructured":"Wang Y, Xiong C, Li Z, Yang Y, Hu J, Wang J, Wang C, Chen G, Zhou R, Ma L, inventors; Ningbo Junjian Biotechnology Co., Ltd, assignee (2024) Self-replicating mRNA sequence and its use in preparing anti-HPV tumor drugs. China patent application CN118725049A"},{"key":"4411_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4049\/jimmunol.180.1.309","volume":"180","author":"S Kreiter","year":"2008","unstructured":"Kreiter S, Selmi A, Diken M, Sebastian M, Osterloh P, Schild H, Huber C, T\u00fcreci O, Sahin U (2008) Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol 180:309\u2013318","journal-title":"J Immunol"},{"key":"4411_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jconrel.2021.05.021","volume":"335","author":"KJ Hassett","year":"2021","unstructured":"Hassett KJ, Higgins J, Woods A, Levy B, Xia Y, Hsiao CJ et al (2021) Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J Control Release 335:237\u2013246","journal-title":"J Control Release"},{"key":"4411_CR28","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1073\/pnas.0801497105","volume":"105","author":"SD Blackburn","year":"2008","unstructured":"Blackburn SD, Shin H, Freeman GJ, Wherry EJ (2008) Selective expansion of a subset of exhausted CD8 T cells by \u03b1PD-L1 blockade. Proc Natl Acad Sci U S A 105:15016\u201315021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4411_CR29","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1126\/science.1229620","volume":"338","author":"MA Paley","year":"2012","unstructured":"Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE et al (2012) Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 338:1220\u20131225","journal-title":"Science"},{"key":"4411_CR30","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1016\/j.cell.2024.04.003","volume":"187","author":"HR Mendez-Gomez","year":"2024","unstructured":"Mendez-Gomez HR, DeVries A, Castillo P, von Roemeling C, Qdaisat S, Stover BD et al (2024) RNA aggregates harness the danger response for potent cancer immunotherapy. Cell 187:2521-2535.e21","journal-title":"Cell"},{"key":"4411_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12943-024-01958-4","volume":"23","author":"HL Qi","year":"2024","unstructured":"Qi HL, Sun ZJ, Gao TL, Yao YL, Wang Y, Li WW et al (2024) Genetic fusion of CCL11 to antigens enhances antigenicity in nucleic acid vaccines and eradicates tumor mass through optimizing T-cell response. Mol Cancer 23:46","journal-title":"Mol Cancer"},{"key":"4411_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0829","volume":"374","author":"RR Goel","year":"2021","unstructured":"Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng WZ, Rosenfeld AM et al (2021) mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374:abm0829","journal-title":"Science"},{"key":"4411_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s40364-024-00692-9","volume":"12","author":"A Shariati","year":"2024","unstructured":"Shariati A, Khani P, Nasri F, Afkhami H, Khezrpour A, Kamrani S et al (2024) mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy. Biomark Res 12:157","journal-title":"Biomark Res"},{"key":"4411_CR34","doi-asserted-by":"publisher","first-page":"eabn3464","DOI":"10.1126\/scitranslmed.abn3464","volume":"15","author":"JR da Silva","year":"2023","unstructured":"da Silva JR, Rodrigues KB, Pelegrin GF, Sales NS, Muramatsu H, Silva MO et al (2023) Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Sci Transl Med 15:eabn3464","journal-title":"Sci Transl Med"},{"key":"4411_CR35","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1126\/science.1082305","volume":"300","author":"DJ Shedlock","year":"2003","unstructured":"Shedlock DJ, Shen H (2003) Requirement for CD4 T-cell help in generating functional CD8 T-cell memory. Science 300:337\u2013339. https:\/\/doi.org\/10.1126\/science.1082305","journal-title":"Science"},{"key":"4411_CR36","doi-asserted-by":"publisher","first-page":"eabj853","DOI":"10.1126\/science.abj9853","volume":"374","author":"J Mateus","year":"2021","unstructured":"Mateus J, Dan JM, Zhang ZL, Moderbacher CR, Lammers M, Goodwin B et al (2021) Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells. Science 374:eabj853","journal-title":"Science"},{"key":"4411_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","volume":"28","author":"RE Tay","year":"2021","unstructured":"Tay RE, Richardson EK, Toh HC (2021) Revisiting the role of CD4\u207a T cells in cancer immunotherapy: new insights into old paradigms. Cancer Gene Ther 28:5\u201317","journal-title":"Cancer Gene Ther"},{"key":"4411_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-55843-9","volume":"16","author":"CJ Maine","year":"2025","unstructured":"Maine CJ, Miyake-Stoner SJ, Spasova DS et al (2025) Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers. Nat Commun 16:456","journal-title":"Nat Commun"},{"key":"4411_CR39","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1016\/j.immuni.2024.07.023","volume":"57","author":"Z Li","year":"2024","unstructured":"Li Z, Obraztsova A, Shang F, Oludada OE, Malapit J, Busch K et al (2024) Affinity-independent memory B cell origin of the early antibody-secreting cell response in na\u00efve individuals upon SARS-CoV-2 vaccination. Immunity 57:2191-2201.e5","journal-title":"Immunity"},{"key":"4411_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D (2018) mRNA vaccines\u2014a new era in vaccinology. Nat Rev Drug Discov 17:261\u2013279","journal-title":"Nat Rev Drug Discov"},{"key":"4411_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3390\/vaccines9020097","volume":"9","author":"AK Blakney","year":"2021","unstructured":"Blakney AK, Ip S, Geall AJ (2021) An update on self-amplifying mRNA vaccine development. Vaccines 9:97","journal-title":"Vaccines"},{"key":"4411_CR42","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3892\/ol.2020.11647","volume":"20","author":"T Zhao","year":"2020","unstructured":"Zhao T, Li Y, Zhang J, Zhang B (2020) PD-L1 expression increased by IFN-\u03b3 via JAK2\u2013STAT1 signaling and predicts poor survival in colorectal cancer. Oncol Lett 20:1127\u20131134. https:\/\/doi.org\/10.3892\/ol.2020.11647","journal-title":"Oncol Lett"},{"key":"4411_CR43","doi-asserted-by":"publisher","first-page":"17810","DOI":"10.1038\/s41598-017-18132-0","volume":"7","author":"JW Moon","year":"2017","unstructured":"Moon JW, Kong SK, Kim BS, Kim HJ, Lim H, Noh K et al (2017) IFN-\u03b3 induces PD-L1 overexpression via JAK2\/STAT1\/IRF-1 signaling in Epstein-Barr virus\u2013positive gastric carcinoma. Sci Rep 7:17810. https:\/\/doi.org\/10.1038\/s41598-017-18132-0","journal-title":"Sci Rep"},{"key":"4411_CR44","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M et al (2017) IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127:2930\u20132940","journal-title":"J Clin Invest"},{"key":"4411_CR45","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB, Anandappa AJ, Sun J et al (2019) Neoantigen vaccine generates intratumoral T cell responses in phase ib glioblastoma trial. Nature 565:234\u2013239","journal-title":"Nature"},{"key":"4411_CR46","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A et al (2024) Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403:632\u2013644","journal-title":"Lancet"},{"key":"4411_CR47","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2018.09.008","volume":"34","author":"R Zappasodi","year":"2018","unstructured":"Zappasodi R, Merghoub T, Wolchok JD (2018) Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell 34:690\u2013714","journal-title":"Cancer Cell"},{"key":"4411_CR48","first-page":"1323","volume":"24","author":"Y-L Li","year":"2010","unstructured":"Li Y-L, Qiu X-H, Shen C, Liu J-N, Zhang J (2010) Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors. Oncol Rep 24:1323\u20131329","journal-title":"Oncol Rep"},{"key":"4411_CR49","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","volume":"9","author":"Y Shi","year":"2024","unstructured":"Shi Y, Shi M, Wang Y, Zhang L, Chen X et al (2024) Progress and prospects of mRNA-based drugs in preclinical and clinical applications. Signal Transduct Target Ther 9:322. https:\/\/doi.org\/10.1038\/s41392-024-02002-z","journal-title":"Signal Transduct Target Ther"},{"key":"4411_CR50","doi-asserted-by":"publisher","first-page":"109804","DOI":"10.1016\/j.isci.2024.109804","volume":"27","author":"T Zhang","year":"2024","unstructured":"Zhang T, Yin H, Li Y, Yang H, Ge K, Zhang J et al (2024) Optimized lipid nanoparticles for organ-selective nucleic acid delivery in vivo. iScience 27:109804. https:\/\/doi.org\/10.1016\/j.isci.2024.109804","journal-title":"iScience"},{"key":"4411_CR51","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","volume":"55","author":"Y Lee","year":"2023","unstructured":"Lee Y, Jeong M, Park J, Kim S, Choi H et al (2023) Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp Mol Med 55:2085\u20132096. https:\/\/doi.org\/10.1038\/s12276-023-01086-x","journal-title":"Exp Mol Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04411-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04411-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04411-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:47:52Z","timestamp":1790293672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04411-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4411"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04411-1","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments involving mice were conducted in strict accordance with the Animal Ethics Procedures and Guidelines of the People\u2019s Republic of China. The experimental protocols were reviewed and approved by the Animal Care and Use Committee of Hangzhou Medical College.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript has not been published or presented elsewhere in part or in entirety, and is not under consideration by another journal. All the authors have approved the manuscript and agree with submission to your esteemed journal.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"236"}}